NCT05339256View on ClinicalTrials.gov

Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Opioid Use Disorder
Interventions
DRUG

Buprenorphine SL

Up to 24 mg per day

OTHER

Telehealth

Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session

OTHER

In-person treatment as usual

in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER